The company, which has inked a memorandum of understanding (MoU) with Austell Laboratories, expects to launch the drug in South Africa by mid-2015.
"Elores is likely to be launched in South Africa by mid-2015, Venus Remedies is projected to generate a cumulative revenue of USD 20 million within five years of the launch of Elores in South Africa," Venus Remedies Chairman and Managing Director Pawan Chaudhary said in a statement.
The overall organised antibacterial market of South Africa is worth US USD 275 million and growing at a compound annual growth rate (CAGR) of 10.5 percent, he added.
"Elores will cater to the needs of about 40 percent segment of this market," Chaudhary said.
Elores is an antibiotic product that counters hospital acquired multidrug resistant infections.
Venus has already filed the common technical document for Elores in Europe and is planning to take this product to other international markets.
Shares of Venus Remedies today closed at Rs 230 a piece on the BSE, down 1.03 per cent from previous close.
Venus Remedies stock price
On December 09, 2013, Venus Remedies closed at Rs 228.95, down Rs 3.45, or 1.48 percent. The 52-week high of the share was Rs 358.05 and the 52-week low was Rs 140.00.
The company's trailing 12-month (TTM) EPS was at Rs 50.97 per share as per the quarter ended September 2013. The stock's price-to-earnings (P/E) ratio was 4.49. The latest book value of the company is Rs 339.42 per share. At current value, the price-to-book value of the company is 0.67.
Anda sedang membaca artikel tentang
Venus inks outlicensing deal for Elores with SA co
Dengan url
http://kebugaranhidup.blogspot.com/2013/12/venus-inks-outlicensing-deal-for-elores.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Venus inks outlicensing deal for Elores with SA co
namun jangan lupa untuk meletakkan link
Venus inks outlicensing deal for Elores with SA co
sebagai sumbernya
0 komentar:
Posting Komentar